{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T17:25:03Z","timestamp":1794677103770,"version":"4.9.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adjuvant cyclin-dependent kinases 4 and 6 (CDK4\/6) inhibitors have improved outcomes in hormone receptor-positive\/human epidermal growth factor receptor 2-negative (HR+\/HER2\u2013) early breast cancer (eBC) in the NATALEE and monarchE trials. However, real\u2011world evidence on the proportion of candidates for adjuvant CDK4\/6 inhibitors and their outcomes within these trial-defined populations remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, population\u2011based cohort study including all patients diagnosed with HR+\/HER2\u2013 eBC in the Hospital District of Helsinki and Uusimaa, Finland, between January 2014 and June 2023. Patients were classified according to NATALEE and\/or monarchE eligibility criteria. Outcomes assessed were invasive disease\u2011free survival (iDFS), distant disease\u2011free survival (DDFS), and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 8911 patients with HR+\/HER2- eBC and a median follow-up of 5.2\u2009years, 40.4% met the NATALEE eligibility criteria and 15.0% met the monarchE criteria. Eligible patients were younger and had higher\u2011grade tumors and greater proliferation rate than non-eligible patients. Five\u2011year outcomes were consistently worse in eligible than ineligible patients (NATALEE: iDFS 82.5% vs 89.6%, DDFS 88.3% vs 94.5%, OS 90.9% vs 95.6%; monarchE: iDFS 76.8% vs 88.4%, DDFS 82.3% vs 93.8%, OS 86.8% vs 94.9%). Metastatic progression occurred 3\u2011 to 6\u2011fold more often in eligible patients. In multivariable models, both NATALEE and monarchE eligibility were associated with distant metastasis, and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Real-world outcomes among NATALEE and monarchE-eligible patients are consistent with results from phase III trial comparator arms. Trial\u2011defined eligibility criteria reliably identify patients with substantially poorer prognosis, supporting risk\u2011adapted adjuvant strategies and the integration of CDK4\/6 inhibitors into clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag419","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:45:08Z","timestamp":1792489508000},"source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and outcomes of NATALEE- and monarchE-eligible early breast cancer in Finland: a regional real-world cohort study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7580-8977","authenticated-orcid":false,"given":"Sari","family":"Voutilainen","sequence":"first","affiliation":[{"name":"Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki , Helsinki FI-00029,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1879-0739","authenticated-orcid":false,"given":"Samuli","family":"Tuominen","sequence":"additional","affiliation":[{"name":"Medaffcon Oy, Espoo, 02150,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-361X","authenticated-orcid":false,"given":"Liisa","family":"Ukkola-Vuoti","sequence":"additional","affiliation":[{"name":"Medaffcon Oy, Espoo, 02150,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Hernesniemi","sequence":"additional","affiliation":[{"name":"Novartis Finland Oy , Espoo, 02100,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Engstr\u00f6m-Risku","sequence":"additional","affiliation":[{"name":"Novartis Finland Oy , Espoo, 02100,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Paulsson","sequence":"additional","affiliation":[{"name":"Novartis Sverige AB , Stockholm, 16440,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9046-8930","authenticated-orcid":false,"given":"Maija","family":"Wolf","sequence":"additional","affiliation":[{"name":"Novartis Finland Oy , Espoo, 02100,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3490-3702","authenticated-orcid":false,"given":"Peeter","family":"Karihtala","sequence":"additional","affiliation":[{"name":"Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki , Helsinki FI-00029,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"2026111411370134200_oyag419-B1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet."},{"key":"2026111411370134200_oyag419-B2","first-page":"287","article-title":"Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN","volume":"5","author":"Zhang","year":"2025","journal-title":"J Natl Cancer Cent."},{"key":"2026111411370134200_oyag419-B3","author":"Cancer statistics. Finnish Cancer Registry","year":"2026"},{"key":"2026111411370134200_oyag419-B4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/metastatic breast cancer: decade report (2005\u20132015)","volume":"39","author":"Cardoso","year":"2018","journal-title":"Breast"},{"key":"2026111411370134200_oyag419-B5","doi-asserted-by":"crossref","first-page":"e1372","DOI":"10.1002\/onco.13813","article-title":"Real-world clinical outcomes in biological subgroups of breast cancer in the hospital district of Southwest Finland","volume":"26","author":"Teerenhovi","year":"2021","journal-title":"Oncologist."},{"key":"2026111411370134200_oyag419-B6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canep.2012.02.007","article-title":"The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality","volume":"36","author":"Youlden","year":"2012","journal-title":"Cancer Epidemiol."},{"key":"2026111411370134200_oyag419-B7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol."},{"key":"2026111411370134200_oyag419-B8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature."},{"key":"2026111411370134200_oyag419-B9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat Rev Cancer."},{"key":"2026111411370134200_oyag419-B10","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med."},{"key":"2026111411370134200_oyag419-B11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.2024.42.16_suppl.541","article-title":"Short-term risk of recurrence in patients (pts) with HR+\/HER2\u2212 early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): a meta-analysis","volume":"42","author":"Curigliano","year":"2024","journal-title":"JCO"},{"key":"2026111411370134200_oyag419-B12","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaoncol.2025.3700","article-title":"Ribociclib plus endocrine therapy in hormone receptor\u2013positive\/ ERBB2 -negative early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial","volume":"11","author":"Fasching","year":"2025","journal-title":"JAMA Oncol."},{"key":"2026111411370134200_oyag419-B13","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med."},{"key":"2026111411370134200_oyag419-B14","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol."},{"key":"2026111411370134200_oyag419-B15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","article-title":"Adjuvant abemaciclib plus endocrine therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes","volume":"42","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol."},{"key":"2026111411370134200_oyag419-B16","doi-asserted-by":"crossref","first-page":"e12533","DOI":"10.1200\/JCO.2024.42.16_suppl.e12533","article-title":"Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+\/HER2\u2212 early breast cancer (EBC) treated with endocrine therapy (ET) in the US","volume":"42","author":"Razavi","year":"2024","journal-title":"JCO"},{"key":"2026111411370134200_oyag419-B17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","article-title":"Overall survival with abemaciclib in early breast cancer","volume":"37","author":"Johnston","year":"2026","journal-title":"Ann Oncol."},{"key":"2026111411370134200_oyag419-B18","doi-asserted-by":"crossref","first-page":"105858","DOI":"10.1016\/j.esmoop.2025.105858","article-title":"Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival","volume":"10","author":"Crown","year":"2025","journal-title":"ESMO Open."},{"key":"2026111411370134200_oyag419-B19","doi-asserted-by":"crossref","first-page":"101471","DOI":"10.1016\/j.lanepe.2025.101471","article-title":"Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study","volume":"59","author":"Liu","year":"2025","journal-title":"Lancet Reg Health Eur."},{"key":"2026111411370134200_oyag419-B20","author":"Valachis"},{"key":"2026111411370134200_oyag419-B21","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2340\/1651-226X.2025.44003","article-title":"Outcomes for patients with high-risk ER-positive, HER2-negative early-stage breast cancer: a Danish real-world study","volume":"64","author":"Jacobsen","year":"2025","journal-title":"Acta Oncol."},{"key":"2026111411370134200_oyag419-B22","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"Von Elm","year":"2014","journal-title":"Int J Surg."},{"key":"2026111411370134200_oyag419-B23","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017","edition":"8th edn"},{"key":"2026111411370134200_oyag419-B24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol."},{"key":"2026111411370134200_oyag419-B25","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system","volume":"25","author":"Hudis","year":"2007","journal-title":"J Clin Oncol."},{"key":"2026111411370134200_oyag419-B26","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol."},{"key":"2026111411370134200_oyag419-B27","doi-asserted-by":"crossref","first-page":"16366","DOI":"10.3390\/ijms242216366","article-title":"The clinical relevance of the NATALEE study: application of the NATALEE criteria to a real-world cohort from two large German breast cancer centers","volume":"24","author":"Sch\u00e4ffler","year":"2023","journal-title":"Int J Mol Sci."},{"key":"2026111411370134200_oyag419-B28","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/jnci\/djaf031","article-title":"Prognostic implications of risk definitions from the monarchE and NATALEE trials","volume":"117","author":"Arecco","year":"2025","journal-title":"J Natl Cancer Inst."},{"key":"2026111411370134200_oyag419-B29","doi-asserted-by":"crossref","first-page":"105304","DOI":"10.1016\/j.esmoop.2025.105304","article-title":"Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+\/HER2\u2212 early breast cancer: a United States electronic health records database analysis","volume":"10","author":"Tarantino","year":"2025","journal-title":"ESMO Open."},{"key":"2026111411370134200_oyag419-B30","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P2-12-02","article-title":"Abstract P2-12-02: Risk of recurrence in real-world (RW) NATALEE- and monarchE-eligible populations of patients with HR+\/HER2- early breast cancer (EBC) in an electronic health record (EHR)-derived database","volume":"31","author":"Tarantino","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026111411370134200_oyag419-B31","first-page":"117","article-title":"The role of Ki-67 in HR+\/HER2- breast cancer: a real-world study of 956 patients","volume":"16","author":"Ma","year":"2024","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"2026111411370134200_oyag419-B32","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12885-022-09557-6","article-title":"A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2\u2212 early breast cancer in the United States","volume":"22","author":"Brown","year":"2022","journal-title":"BMC Cancer."},{"key":"2026111411370134200_oyag419-B33","doi-asserted-by":"crossref","first-page":"17588359231178125","DOI":"10.1177\/17588359231178125","article-title":"Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib\u2009+\u2009endocrine therapy versus endocrine therapy alone in patients with HR+\/HER2\u2212 early breast cancer","volume":"15","author":"Slamon","year":"2023","journal-title":"Ther Adv Med Oncol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag419\/72128456\/oyag419.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/12\/oyag419\/72128456\/oyag419.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/12\/oyag419\/72128456\/oyag419.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:37:13Z","timestamp":1794674233000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag419\/8943988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,11,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag419","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,12]]},"published":{"date-parts":[[2026,10,20]]},"article-number":"oyag419"}}